NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors<
07 Jan 2020

Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors

Former Celgene Business Development Head Brings Entrepreneurial Expertise and Life Science Business Leadership
07 Jan 2020

Galecto and PharmAkea merge to create strong clinical-stage company developing first-in-class therapeutics in fibrosis and cancer

Galecto and PharmAkea, Inc., today announced the two companies will merge.
04 Dec 2019

Anaconda biomed secures €20 million round of funding

Anaconda Biomed S.L., has closed €20 million in new funding.
05 Nov 2019

Anaconda biomed announces first-in-human study of Next-generation thrombectomy system

Anaconda Biomed has announced the completion of initial patient cases in a first-in-human study at Hospital Vall d’Hebron in Barcelona.
30 Oct 2019

Sanifit announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint in slowing the progression of cardiovascular calcification in patients on hemodialysis

Sanifit, today announced that the international Phase 2b CaLIPSO study of SNF472 in patients with end stage kidney disease (ESKD) on hemodialysis has met its primary endpoint.
17 Oct 2019

Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia

Minoryx Therapeutics, today announces that its lead drug candidate, leriglitazone, has been granted Orphan Drug Designation in Friedreich’s Ataxia by the US Food and Drug Administration.
Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at the American Academy of Ophthalmology 2019 Annual Meeting<
15 Oct 2019

Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at the American Academy of Ophthalmology 2019 Annual Meeting

Light-Activated AU-011 has the Potential to be the First FDA Approved Therapy for the Primary Treatment of Choroidal Melanoma
09 Oct 2019

Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia

Minoryx Therapeutics, today announces that it has completed recruitment in the FRAMES phase 2 clinical trial of its novel PPARγ agonist, leriglitazone (MIN-102), in patients with Friedreich’s Ataxia.
01 Oct 2019

AM-Pharma Expands its Senior Team in Preparation for a Pivotal Phase III Trial of recAP in Acute Kidney Injury

AM-Pharma B.V. today announces that it has expanded its senior team with two appointments. Dr. Juliane Bernholz has joined as Chief Operating Officer (COO), and Ms. Kristie Bass as VP Clinical Operations (VP Clin Ops).
11 Sep 2019

CorWave Presented First Successful In Vivo 60-Day Study on Its Innovative LVAD Cardiac Support Device

CorWave announced that it successfully completed its first 60-day preclinical study to evaluate its Left Ventricular Assist Device (LVAD).

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.